Genomic analysis of the evolution of fluoroquinolone resistance in Mycobacterium tuberculosis prior to tuberculosis diagnosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 11, 2016, Pages 6600-6608

  Zhang, Danfeng ^a,b   Gomez, James E ^a   Chien, Jung Yien ^c,d   Haseley, Nathan ^a   Desjardins, Christopher A ^a   Earl, Ashlee M ^a   Hsueh, Po Ren ^d   Hung, Deborah T ^a,e,f  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MINNAN NORMAL UNIVERSITY   (China)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ISONIAZID; OFLOXACIN; RIFAMPICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; GENE FREQUENCY; HUMAN; MOLECULAR CLONING; MYCOBACTERIUM TUBERCULOSIS; NEXT GENERATION SEQUENCING; PATIENT SELECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; CELL CLONE; CLASSIFICATION; DRUG EFFECTS; GENETIC SELECTION; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; MUTATION; PHYLOGENY; PNEUMONIA, BACTERIAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CLONE CELLS; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVOLUTION, MOLECULAR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PHYLOGENY; PNEUMONIA, BACTERIAL; SELECTION, GENETIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84995489169     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00664-16     Document Type: Article

References (41)

1. World Health Organization. 2015. Global tuberculosis report 2015. WHO/HTM/TB/2015.22. World Health Organization. Geneva, Switzerland.
2. Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. 2015. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother 59:4026-4030. http://dx.doi.org/10.1128/AAC.00105-15.
3. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2011.6. World Health Organization. Geneva, Switzerland.
4. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA, Team RT. 2014. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371:1599-1608. http://dx.doi.org/10.1056/NEJMoa1314210.
5. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F N. Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C, OFLOTUB/Gatifloxacin for Tuberculosis Project. 2014. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371:1588-1598. http://dx.doi.org/10.1056/NEJMoa1315817.
6. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ, Consortium RE. 2014. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371:1577-1587. http://dx.doi.org/10.1056/NEJMoa1407426.
7. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. 2015. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385:1738-1747. http://dx.doi.org/10.1016/S0140-6736(14)62002-X.
8. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27-S72.
9. Kim ES, Hooper DC. 2014. Clinical importance and epidemiology of quinolone resistance. Infect Chemother 46:226-238. http://dx.doi.org/10.3947/ic.2014.46.4.226.
10. Drlica K, Malik M. 2003. Fluoroquinolones: action and resistance. Curr Top Med Chem 3:249-282. http://dx.doi.org/10.2174/1568026033452537.
11. Mayer C, Takiff H. 2014. The molecular genetics of fluoroquinolone resistance in Mycobacterium tuberculosis. Microbiol Spectr 2:MGM2-0009-2013. http://dx.doi.org/10.1128/microbiolspec.MGM2-0009-2013.
12. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819-831. http://dx.doi.org/10.1093/jac/dkr566.
13. Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, Rodwell T. 2015. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One 10:e0120470. http://dx.doi.org/10.1371/journal.pone.0120470.
14. Ho J, Jelfs P, Sintchenko V. 2014. Fluoroquinolone resistance in nonmultidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int J Infect Dis 26:149-153. http://dx.doi.org/10.1016/j.ijid.2014.03.1388.
15. Streicher EM, Bergval I, Dheda K, Bottger EC, Gey van Pittius NC, Bosman M, Coetzee G, Anthony RM, van Helden PD, Victor TC, Warren RM. 2012. Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrob Agents Chemother 56:2420-2427. http://dx.doi.org/10.1128/AAC.05905-11.
16. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR. 2014. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 58:3270-3275. http://dx.doi.org/10.1128/AAC.02066-13.
17. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard. National Committee for Clinical Laboratory Standards, Wayne, PA.
18. Somerville W, Thibert L, Schwartzman K, Behr MA. 2005. Extraction of Mycobacterium tuberculosis DNA: a question of containment. J Clin Microbiol 43:2996-2997. http://dx.doi.org/10.1128/JCM.43.6.2996-2997.2005.
19. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, Cuomo CA, Zeng Q, Wortman J, Young SK, Earl AM. 2014. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS One 9:e112963. http://dx.doi.org/10.1371/journal.pone.0112963.
20. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59:860-865. http://dx.doi.org/10.1093/jac/dkm061.
21. Ross MG, Russ C, Costello M, Hollinger A, Lennon NJ, Hegarty R, Nusbaum C, Jaffe DB. 2013. Characterizing and measuring bias in sequence data. Genome Biol 14:R51. http://dx.doi.org/10.1186/gb-2013-14-5-r51.
22. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. http://dx.doi.org/10.1371/journal.pone.0039754.
23. Colangeli R, Arcus VL, Cursons RT, Ruthe A, Karalus N, Coley K, Manning SD, Kim S, Marchiano E, Alland D. 2014. Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans. PLoS One 9:e91024. http://dx.doi.org/10.1371/journal.pone.0091024.
24. Eldholm V, Norheim G, von der Lippe B, Kinander W, Dahle UR, Caugant DA, Mannsaker T, Mengshoel AT, Dyrhol-Riise AM, Balloux F. 2014. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol 15:490. http://dx.doi.org/10.1186/s13059-014-0490-3.
25. Kanduma E, McHugh TD, Gillespie SH. 2003. Molecular methods for Mycobacterium tuberculosis strain typing: a users guide. J Appl Microbiol 94:781-791. http://dx.doi.org/10.1046/j.1365-2672.2003.01918.x.
26. Grossman RF, Hsueh PR, Gillespie SH, Blasi F. 2014. Communityacquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. Int J Infect Dis 18:14-21. http://dx.doi.org/10.1016/j.ijid.2013.09.013.
27. Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-Grochowska K, Shandro C, Manfreda J, Senthilselvan A, Elzainy A, Marrie T. 2009. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 48:1354-1360. http://dx.doi.org/10.1086/598196.
28. Van Der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR. 2015. A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis. Epidemiol Infect 143:960-965. http://dx.doi.org/10.1017/S0950268814003136.
29. Kent PT, Kubica GP. 1985. Antituberculosis chemotherapy and drug susceptibility testing, p 159-184. In Kent PT, Kubica GP (ed), Public health mycobacteriology: a guide for the level III laboratory. Centers for Disease Control and Prevention, Atlanta, GA.
30. Bemer P, Palicova F, Rusch-Gerdes S, Drugeon HB, Pfyffer GE. 2002. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 40:150-154. http://dx.doi.org/10.1128/JCM.40.1.150-154.2002.
31. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NT, Jones-Lopez EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D. 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48:229-237. http://dx.doi.org/10.1128/JCM.01463-09.
32. Ardizzoni E, Fajardo E, Saranchuk P, Casenghi M, Page AL, Varaine F, Kosack CS, Hepple P. 2015. Implementing the Xpert(R) MTB/RIF diagnostic test for tuberculosis and rifampicin resistance: outcomes and lessons learned in 18 countries. PLoS One 10:e0144656. http://dx.doi.org/10.1371/journal.pone.0144656.
33. Boehme C. 2015. Looking ahead: the new TB diagnostic pipeline. http://www.stoptb.org/wg/gli/assets/documents/M7/4.BOEHME-NewTBdiagnosticspipeline.pdf
34. Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, Steingart KR, Dheda K. 2014. The diagnostic accuracy of the Geno-Type((R)) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 10:CD010705. http://dx.doi.org/10.1002/14651858.CD010705.pub2.
35. Folkvardsen DB, Thomsen VO, Rigouts L, Rasmussen EM, Bang D, Bernaerts G, Werngren J, Toro JC, Hoffner S, Hillemann D, Svensson E. 2013. Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods. J Clin Microbiol 51:4220-4222. http://dx.doi.org/10.1128/JCM.01602-13.
36. Pang Y, Liu G, Wang Y, Zheng S, Zhao YL. 2013. Combining COLDPCR and high-resolution melt analysis for rapid detection of low-level, rifampin-resistant mutations in Mycobacterium tuberculosis. J Microbiol Methods 93:32-36. http://dx.doi.org/10.1016/j.mimet.2013.01.008.
37. Didelot X, Bowden R, Wilson DJ, Peto TE, Crook DW. 2012. Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 13:601-612. http://dx.doi.org/10.1038/nrg3226.
38. Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, Eyre DW, Wilson DJ, Hawkey PM, Crook DW, Parkhill J, Harris D, Walker AS, Bowden R, Monk P, Smith EG, Peto TE. 2013. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 13:137-146. http://dx.doi.org/10.1016/S1473-3099(12)70277-3.
39. Takiff HE, Feo O. 2015. Clinical value of whole-genome sequencing of Mycobacterium tuberculosis. Lancet Infect Dis 15:1077-1090. http://dx.doi.org/10.1016/S1473-3099(15)00071-7.
40. Pankhurst LJ, Del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, Fermont JM, Gascoyne-Binzi DM, Kohl TA, Kong C, Lemaitre N, Niemann S, Paul J, Rogers TR, Roycroft E, Smith EG, Supply P, Tang P, Wilcox MH, Wordsworth S, Wyllie D, Xu L, Crook DW, COMPASS-TB Study Group. 2016. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med 4:49-58. http://dx.doi.org/10.1016/S2213 -2600(15)00466-X.
41. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, Earle S, Pankhurst LJ, Anson L, de Cesare M, Piazza P, Votintseva AA, Golubchik T, Wilson DJ, Wyllie DH, Diel R, Niemann S, Feuerriegel S, Kohl TA, Ismail N, Omar SV, Smith EG, Buck D, McVean G, Walker AS, Peto TE, Crook DW, Iqbal Z. 2015. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun 6:10063. http://dx.doi.org/10.1038/ncomms10063.